Strategic focus Immune-Onc is a private, clinical-stage oncology company concentrating on myeloid cell inhibitory receptors with a differentiated pipeline, presenting opportunities to discuss strategic collaborations or licensing around IO-108, IO-202, IO-106 and IO-312 for cancer indications and potential combination strategies.

Phase progression Lead assets IO-108 and IO-202 are advancing through early clinical stages with IO-202 in Phase 1b and 1b/2 for AML, CMML, and solid tumors, signaling a readiness for early partnering discussions, co-development, or milestone-driven deals with biotech or larger pharma with hematology oncology focus.

Partnership history Past collaborations, including BeiGene in 2022 for combination trials with tislelizumab, demonstrate openness to external partnerships and favorable track record for joint development, offering a credible pathway for new alliance opportunities, especially in China and global markets.

Funding momentum Recent financing activity, including a $25M Series B extension and ongoing private funding, indicates strong investor confidence and a runway that supports business development efforts, enabling BD teams to pursue durable partnerships and co-development programs.

Market readiness A focused platform targeting LILRB receptors with first-in-class or unique mechanisms positions Immune-Onc for competitively differentiated safety and efficacy profiles, presenting a compelling value proposition for pharma partners seeking novel myeloid checkpoint therapies and combination strategies.